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Abstract
Dogs are the main source of human cystic echinococcosis. An oral vaccine would be an important contribution to control
programs in endemic countries. We conducted two parallel experimental trials in Morocco and Tunisia of a new oral vaccine
candidate against Echinococcus granulosus in 28 dogs. The vaccine was prepared using two recombinant proteins from
adult worms, a tropomyosin (EgTrp) and a fibrillar protein similar to paramyosin (EgA31), cloned and expressed in a live
attenuated strain of Salmonella enterica serovar typhimurium.
In each country, five dogs were vaccinated with the associated EgA31 and EgTrp; three dogs received only the vector
Salmonella; and six dogs were used as different controls. The vaccinated dogs received two oral doses of the vaccine 21 d
apart, and were challenged 20 d later with 75,000 living protoscoleces. The controls were challenged under the same
conditions. All dogs were sacrificed 26–29 d postchallenge, before the appearance of eggs, for safety reasons.
We studied the histological responses to both the vaccine and control at the level of the duodenum, the natural localization
of the cestode. Here we show a significant decrease of parasite burden in vaccinated dogs (70% to 80%) and a slower
development rate in all remaining worms. The Salmonella vaccine EgA31-EgTrp demonstrated a high efficacy against E.
granulosus promoting its potential role in reducing transmission to humans and animals.
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Introduction
Cystic echinococcosis, also called hydatidosis, represents a severe
public health and livestock problem, particularly in developing
countries [1–3]. The causative agent is the cestode Echinococcus
granulosus. The adult stage may be found in the small intestine of
canine carnivores.Growthofthelarvalstage throughout the internal
organs, especially the liver and lungs, causes clinical signs in the
intermediate hosts, such as sheep, cattle, and camels. Humans may
also become host to this metacestode. Usually, however, interme-
diate hosts become infected by grazing on vegetation contaminated
by eggs shed by adult worms via canine feces [4].
In various endemic areas, prevention and control programs have
been established [5]. These programs usually involve the repeat
treatment of dogs with praziquantel alongside the establishment of
health education programs. However, such programs represent a
significant financial burden for developing countries.
A vaccine against hydatidosis (the disease caused by the larval
stage of the parasite), or echinococcosis (the disease caused by the
adult stage), is thus highly desirable in order to provide long-term
prevention of the disease and to complement control programs.
An effective vaccine against ovine hydatidosis, based on a
recombinant protein from parasite oncospheres (first larval stage
of the parasite), has been developed that targets the larval stage of
the parasite [6]. If used in the field, this vaccine would need to be
administered to all animals in a herd, which may be very costly to
control programs. In contrast, a vaccine directed at protecting
dogs against the adult worm would have to be given to only a few
animals to protect the environment, because dogs are less
numerous than other animals in the herd. Mathematical modeling
has recently confirmed the possible utility of this strategy [7], and
several authors have demonstrated its feasibility by showing that
dogs can develop protective immunity against E. granulosus [8,9].
Based on these reports, subcutaneously injected anti-
echinococcosis vaccines have been prepared from soluble native
protoscolex (scoleces situated in brood capsules) proteins as well as
from recombinant proteins normally expressed by mature adult
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egg development.
Here we describe a vaccine that uses a live attenuated Salmonella
mutant strain as a vector to deliver two recombinant proteins
expressed by the adult stage of E. granulosus: tropomyosin (EgTrp)
and (EgA31), which share some sequence elements with para-
myosins. The vaccine is intended to protect domestic and stray dogs
aswellaswildcanidsfrominfectionwithE.granulosus.West ud ie dt he
histological and immunological responses to both the vaccine and to
a challenge at the level of the upper duodenum in dogs.
Materials and Methods
Plasmids and bacterial strains
EgA31 and EgTrp are recombinant proteins. As described by
Saboulard et al. [11], a PstI/DraI cDNA fragment of the EgA31
cDNA (GenBank [http://www.ncbi.nlm.nih.gov/] accession no.
AF067807) was cloned into the PQE80L expression vector
(Qiagen). Plasmid pQE11-EgTrp encoding the C terminus of E.
granulosus antigen EgTrp and plasmid pTECH2 1994 have been
described elsewhere [12,13].
S. enterica serovar typhimurium (S. typhimurium) aroC strain LVR01
suitable for oral immunization of dogs is described elsewhere [14].
Cloning and expression of EgA31 and EgTrp as TetC
fusions in the Salmonella vaccine strain
An immunogenic fragment encoding aa 168–246 [11] from
EgA31 was amplified by PCR from pQE80[egA31] using the
primers EgA3 (forward primer: 59-CATGGATCCGCTGAAAA-
ACAAGCCATGGAT-39), and EgA4 (reverse primer: 59-ATG-
AAGCTTAATTTCAGCTTTCTGCTC-39). Forward and re-
verse primers contained BamHI and SpeI restriction sites
(underlined) to facilitate directional cloning into pTECH as
previously described [14].
The EgTrp (GenBank accession no. AAB65799) was amplified by
PCR from pQE11-EgTrp using primers TrpF (forward primer:
59-CGCGGATCCGAAACATCTACTAAGCTTGACG-39), and
TrpR (reverse primer: 59-CCCAAGCTTTCAGAAGGAAGT-
GAGCTCCGCG-39). Forward and reverse primers contained
BamHI and SpeI restriction sites (underlined) to facilitate directional
cloning into pTECH.
Each of the PCR products was ligated into the pTECH plasmid,
which had been previously digested with the same enzymes, and
the ligation product was transformed into E. coli strain TG2.
Transformant colonies were evaluated by DNA restriction analysis
of the plasmid. Expression of the TetC fusions was tested by
Western blotting on lysates of bacteria harboring the construct,
using anti-TetC serum and either anti-EgA31 or anti-EgTrp sera
as probes, as previously described [15]. The constructs were then
transferred to Salmonella LVR01 and tested again for expression
of the fusion protein.
Experimental animals
All work with dogs was conducted following international
guidelines on the use of animals for experimentation (recommen-
dation of the European Commission No L 358, ISSN 0378-6978).
Dogs of common breeds, between 1 and 6 mo of age, were
purchased locally in Tunisia and Morocco and kept in approved
facilities for 2 mo before use.
A total of 28 dogs were used in this study, 14 in each country.
Dogs were divided into four groups, with the number, sex, and age
detailed in Table 1.
Group 1: Ten animals. All were vaccinated with EgA31 and
EgTrp, before being challenged with protoscoleces.
Group 2: Six animals. All received the vector Salmonella not
expressing any E. granulosus antigen, before being challenged with
protoscoleces.
Group 3: 12 animals. All were controls: Five dogs received a
mock vaccination with 0.1 mM PBS before being infected with
protoscoleces; five dogs were only infected with protoscoleces; and
two dogs were the noninfected (negative) controls.
Vaccination protocols and challenge
For oral immunization, dogs were starved 12 h before being
allowed to ingest 5610
10 recombinant bacteria in 2 ml of PBS, or
PBS alone as previously described [15]. Animals received two
doses 21 d apart. Bacterial cultures were prepared just before each
vaccination dose. Weekly blood samples were taken after
immunization ,and sera were stored at 220uC until testing.
Twenty days after the last dose of Salmonella, all animals were
orally challenged with 7.5610
4 live protoscoleces obtained from
liver cysts recovered from sheep. The viability of protoscoleces was
verified before challenge. Dogs were euthanized by intravenous
injection of pentobarbital 26–29 d post-challenge.
Tissue collection
Immediately following euthanasia, full-thickness sections of the
experimental and control dogs’ proximal duodenum (always
within 10–15 cm from the pylorus) were collected for immuno-
staining and histological examination.
Worms were recovered by scraping the intestinal mucosa
followed by several washings with 0.9 N NaCl solution and a series
of sedimentation steps.
Preparation for immunostaining and histological
examination
Tissues were fixed in 10% neutral-buffered formalin, embedded
in paraffin wax, sectioned at 6 mm, and either stained with
haematoxylin for routine histological evaluation or transferred onto
poly-l-lysine–pretreated slides for immunohistochemical studies.
To identify T cells and plasma cells in sections, we used a panel of
primary antibodies to: CD3, lambda (l), kappa (k), IgA, IgM, as well
Author Summary
In many countries in the world, livestock and humans are
affected with hydatid disease, which is caused by the
development, in the viscera, of the larval stage of the
cestode Echinococcus granulosus. They become infected by
ingesting the eggs of this parasite, which are passed in the
feces of the dog—the host of the adult worm. Domestic
dogs are key in the transmission to livestock and humans.
This disease remains a major economic and public health
problem in affected countries. Because dogs are quickly
reinfected, control programs in these locations include
monthly anthelmintic deworming. These control measures,
however, are burdensome for the owner, so they often fail.
In contrast, vaccination can take place in control programs
at different stages of the parasite life cycle. For example,
currently an effective recombinant vaccine for sheep has
been developed that should work indirectly to reduce
infection in dogs, which tend to eat sheep offal. However,
we propose that a recombinant oral vaccine given to the
small number of dogs keeping the herd would decrease
the number of Echinococcus granulosus adult worms and,
consequently, the number of infective eggs. This measure
would help reduce the contamination risk factors for
humans and livestock, and would be cost-effective for the
owners of the dogs.
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Biomeda). Briefly, fixed sections were passed through graded alcohol
to PBS (0.01 M [pH 7.2]), then lightly digested in stabilized enzyme
mixture (Auto/Zyme Reagent Set; Biomeda) for 10 min at 37uCt o
break the disulphide bridges and enhance antigen retrieval. After
one wash in PBS, sections were heated in 10 mM citrate buffer
(pH 6.0) for 40 min at 90uC in a double boiler.
Endogenous peroxidase activity was blocked by incubation with
hydrogen peroxide (3% v/v) in PBS for 10 min, and slides were
then incubated for 10 min with a blocking solution (tissue
conditioner, Biomeda) to reduce nonspecific background activity.
Sections were incubated with primary antibody for 1 h and
sequentially incubated with biotinylated secondary antibody
(Autoprobe II, Biomeda) for 30 min. Prior to use, the secondary
antibody was incubated for 30 min with 10% (v/v) dog serum.
Slides were then incubated with streptavidin-biotin horseradish
peroxidase complex (Autoprobe II, Biomeda) for 30 min. All
incubations were performed at room temperature.
We used PBS to wash sections three times between each
incubation step, to perform all dilutions, and to replace primary
antibodies for control purposes.
Binding of the streptavidin-biotin conjugate was visualized by
addition of 3,39-diaminobenzidine terahydrochloride and hydro-
gen peroxide (Autoprobe II, Biomeda); sections were counter-
stained with haematoxylin.
Examination of sections and labeled cell quantification
To ensure homogeneity of the analyses, all sections were coded
and analyzed in a blinded fashion by the same investigator.
Samples were examined with an Olympus BX 50 microscope.
For each section, we counted positively stained cells in the
lamina propria of villi. Ten areas of the duodenal mucosa
including one or more villi (except those just above Peyer’s
patches), were chosen at 206 objective, digitized with a Nikon
Coolpix 4500 digital camera, and then transferred to a computer
by means of Nikon software (Eclipse net). Lamina propria from
each villus, from base to tip, was delineated on the computer
screen (excluding epithelium and large vessels), and positively
stained cells within each region were manually counted.
Electron microscopy methods
Fragments (less than 1 mm thick) of the different intestinal
segments were fixed in 2% glutaraldehyde–sodium cacodylate/
HCl 0.1 M (pH 7.4) for 2 h at 4uC. After washing in socium
cacodylate/HCl 0.2 M (pH 7.4), the samples were post-fixed in
1% OsO4–sodium cacodylate/HCl 0.15 M (pH 7.4) for 1 h at
4uC, and dehydrated in graded (from 30% to 100%) ethanol.
For transmission electron microscopy, samples were impregnated
in Epon and flat-embedded in order to define the orientation of the
tissue sample (epithelio-connective interface) for sectioning. After
polymerization at 60uC for 3 d, thin sections were obtained on an
RMC MTX ultramicrotome: semi-thin sections (1 mm thick)
deposited on glass slides were stained according to Richardson et
al. [16] with methyleneblueandAzur II;and ultra-thin sections(60–
80 nm) adhered to copper grids were contrasted according to
Reynolds [17] with uranyl acetate and lead citrate. Sections were
observed using a Jeol 1200 CX transmission electron microscope
equipped with numerical camera SIS Megaview II. Iconography
was treated with AnalySIS software.
ELISA determination of antibody responses
96-well micro plates (Nunc-Maxisorb) were coated with 1 mg/
ml of each recombinant protein in 30 mM carbonate-bicarbonate
buffer (pH 9.6). After overnight incubation at 4uC, the plates were
washed with 0.05% Tween 20 in PBS (PBS-Tween), and blocked
with PBS-Tween containing 1% bovine serum albumin for 2 h at
37uC. Pools of dog serum made up in PBS-Tween were added to
triplicate wells and the plates incubated at 37uC for 2 h. After
three washes with PBS-Tween, 100 ml/well of each of the diluted
specific antibodies (1:100), the monoclonal goat anti-dog IgG
(Sigma-Aldrich), IgA, and IgE (Interchim) were added. After
incubation for 2 h at 37uC, the plates were washed, and 100 ml/
well of peroxidase-labeled rabbit anti-goat IgG (Sigma-Aldrich)
diluted 1:5,000 in PBS-Tween was added. After incubation (1 h at
Table 1. Age, Sex, and Status of the Group of Dogs Used in the Experiments in Morocco and Tunisia
Group Morocco Tunisia
Dog Identification Age-Sex Status Dog Identification Age-Sex Status
Group 1: Received EgA31-EgTrp
expressed in Salmonella
11 5-F Vaccinated 01 5-F Vaccinated
10 6-F Vaccinated 04 5-M Vaccinated
07 3-M Vaccinated 05 5- M Vaccinated
06 3-F Vaccinated 06 6-F Vaccinated
04 3-M Vaccinated 10 5-F Vaccinated
Group 2: Received the vector not
expressing the antigen
05 3-M Salmonella 11 5-F Salmonella
16 3-F Salmonella 12 5-F Salmonella
01 5-M Salmonella 14 4-F Salmonella
Group 3: Controls 08 3-F Control PBS 03 6-F Control PBS
09 3-M Control PBS 08 7-M Control PBS
19 3-F Control PBS 02 4-M Infected control
13 3-F Infected control 15 4-M Infected control
18 3-M Infected control 37 10-M Infected control
16 5-M Negative control 36 5-M Negative control
doi:10.1371/journal.pntd.0000125.t001
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developed with the substrate 3,39,5,59-tetramethylbenzene-dihy-
drochloride (Sigma-Aldrich). Optical densities were read at
450 nm with an ELISA plate reader (Microplate Reader, Bio-
Rad Laboratories). Sera from the control dogs (nonvaccinated and
noninfected) were pooled and used as a negative control to
measure the background activity in all experiments.
Statistical analysis
INSTAT software (GraphPad) was used for the statistical
studies. One-way analysis of variance (ANOVA), and the Dunnett
multiple comparisons post-test were employed. Statistical differ-
ences with P,0.05 were considered significant.
Results
Cestode counts
We counted the number of worms in all groups of animals.
Total and average numbers are presented in Table 2. Results of
the trial in Morocco showed a 79% reduction in the number of
cestodes in vaccinated dogs compared with nonvaccinated,
noninfected controls. Results did, however, vary among animals:
one dog (number 4) from the vaccinated group had the largest
worm load (unpublished data), suggesting that the vaccine did not
exert any protective effect in this animal.
Similar to those seen in Morocco, the results from the trial
carried out in Tunisia showed a 74% reduction in the number of
worms in vaccinated compared with control dogs (Table 2).
Worm size variation
We measured the sizes of 50 randomly chosen worms per
experimental group and recorded the percentage of developed
($5 mm)versusunderdeveloped(,5 mm)worms.Inthevaccinated
dogs, 40% of the worms were small, whereas in infected control
dogs, small worms represented only 15% of the total population. We
observed a similar distribution in the Tunisian experiments. It is
worth noting here that a decrease in the number of parasites and a
delay in their growth rate are considered to be two criteria for the
effectiveness of a vaccine against the adult worm.
Histological, immunostaining, and electron microscope
results
Haematoxylin-stained sections were examined prior to immu-
nostaining. Table 3 shows the number of cells/mm
2 that stained
positively with the antibodies studied in each group of dogs. For
each antibody, we assessed a mean area of 0.58 mm
2. The results
from the vaccinated group exclude dog 4, which had the large
parasite load.
We observed CD3 labeling characterized by a strong staining of
the cytoplasm of positive cells with reinforcement just beneath the
cell membrane. CD3+ cells had small lymphocyte morphology.
These cells were distributed predominantly in the upper half of the
villus with decreasing density towards the base (Figure 1C and 1D)
In the lamina propria, the k-, l-, IgA-, and IgM-positive cells
exhibited typical plasma cell morphology. The markers strongly and
uniformly stained the cytoplasm of cells. We found considerably
more l-positive plasma cells than -positive cells (ratio l/k of 5), and
IgA-containing plasma cells predominated with fewer IgM-positive
cells (ratio IgA/IgM of 6.6). We observed the majority of IgA-
containing cells located in the lower half of the villi (Figure 1A and
1B) and IgM-containing cells at the base of the villi.
Electron microscope (Figure 1E and 1F) and immunostaining
results confirmed that immunized dogs mounted a strong
inflammatory response compared to infected controls upon
challenge. The interstitium was invaded by an immunocompetent
cell infiltrate with numerous plasma cells and lymphocytes. We
also identified many activated lymphocytes, characterized by their
nucleus-cytoplasm ratio (,1), in Peyer’s patches.
Antibody responses against recombinant Echinococcus
proteins
The quality of the immune response, and the pattern of the
antibody subclass (IgG, IgA, IgE) were determined by ELISA. The
IgA and IgE responses induced by the recombinant proteins were
Table 2. Experiment Done in Morocco and Tunisia: Worms Counted in Each Group of Dogs
Group Dogs (n) Morocco Tunisia
No. of Worms Mean/Dog No. of Worms Mean/Dog
Vaccinated 5 2,825 (170–1,130) 565
** # 3,904 (160–1,350) 650
** #
Salmonella alone 3 4,495 (265–3,570) 1,498
** 4,060 (508–2,100) 1,350
**
Control 3 15,720 (390–8,640) 2,620 12,312 (160–6,500) 2,460
**P,0.01, Dunnett multiple comparisons test. P-value as compared with dogs from control groups.
#P,0.05, Dunnett multiple comparisons test. P-value as compared with dogs that received only Salmonella.
doi:10.1371/journal.pntd.0000125.t002
Table 3. Number of Positive Cells per Square Millimeter after
Immunostaining with Various Antibodies in the Villous Lamina
Propria of the Duodenum
Antibodies Vaccinated Dogs
Dogs Receiving only
Salmonella Control
CD3 591* 1,414 1,245
Lambda (l) 1,912
## 1,177 1,591
Kappa (k) 339 297 324
IgA 1,460 1,048 1,395
IgM 189 193 217
l+k/CD3 3.81
# 1.04 3.71
IgA+IgM/CD3 2.79
## * 0.88 1.45
The average of Lambda positive cells was 1,594 per mm
2 and of Kappa positive
cells 322 per mm
2; thus the l/k ratio is 5. The average of IgA positive cells was
1,335 per mm
2 and of IgM positive cells 202 per mm
2, thus the IgA/IgM ratio is
6.6.
*P,0.05, Dunnett multiple comparisons test.
##P,0.01, Dunnett multiple comparisons test.
#P,0.05, Dunnett multiple comparisons test.
#P-value as compared with dogs who received only Salmonella.
**P-value as compared with dogs from control groups.
doi:10.1371/journal.pntd.0000125.t003
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PLoS Neglected Tropical Diseases | www.plosntds.org 4 2008 | Volume 2 | Issue 1 | e125Figure 1. Immunocompetent Cell Responses at the Level of the Duodenum of Vaccinated and Control Dogs. (A) Duodenum of a
vaccinated dog: The interstitial infiltrate of immunocompetent cells are labelled with a polyclonal rabbit antiserum specific for the Fc fragment from
IgA of dog. IgA. Binding is visualized by the peroxidase reaction (brown cells) and hematoxylin counter stained. (B) Duodenum of an infected control
dog: The interstitial infiltrate of immunocompetent cells are labelled with a polyclonal rabbit antiserum specific for the Fc fragment from IgA of dog.
IgA. Binding is visualized by the peroxidase reaction (brown cells) and hematoxylin counter stained. (C) Duodenum of a vaccinated dog: T cells in the
interstitium at the top of the villi are immunolabelled with rat antihuman CD3IgG1, clone number CD3-12. Binding is visualized by the peroxidase
reaction (brown cells) and hematoxylin counterstained. (D) Duodenum of a control infected dog: T cells in the interstitium at the top of the villi are
immunolabelled with rat antihuman CD3IgG1, clone number CD3-12. Binding is visualized by the peroxidase reaction (brown cells) and hematoxylin
counterstained. (E) Duodenum of a vaccinated dog: on the right: the base of the villus: a goblet cell (GC) is included in the epithelium. Brush border
(BB) is present at the apex of epithelial cells (EC); On the left: the subjacent interstitium is invaded by an immunocompetent cell infiltrate: plasma cells
(PC) are numerous. LC, lymphocyte. (F) Duodenum of a control infected dog: on the right epithelial cells (EC) from the villus then basal lamina (BL). On
the left the subjacent interstitium shows the presence of fibroblast (FC) and immunocompetent cells: plasma cell (Pl) and polynuclear cell (PN).
doi:10.1371/journal.pntd.0000125.g001
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vaccinated group and controls.
Discussion
To our knowledge, this is the first report of protection induced in
dogs againstthe adult stage ofE.granulosusafter oral vaccination with
a recombinant parasite protein. We have demonstrated the efficacy
of the vaccine in two separate trials, each in a different country.
Vaccination caused a decrease of more than 70% in the number of
cestodes, and of a slower development rate of those recovered from
vaccinated animals. Suppression of cestode development has also
been observed recently [38] following the injection of a vaccine
composed of recombinant EgM proteins.Out of consideration of the
risk of infection to technical staff working with the patent infection in
the dogs, we chose not to estimate the number of eggs in gravid
segments, notwithstanding the opportunity offered by the strong
expression of EgA31 in eggs and its potential usefulness as a marker
[11]. We have demonstrated that a field vaccine based on this
technology could be formulated into baits to target domestic and
stray dogs in endemic countries.
Hydatid disease remains an important risk to human health and
has a large economic impact. Several vaccine trials have thus been
carried out in dogs, mainly using protoscolex membranes [8,9] or
excretory–secretory antigens from adult cestodes [18,19]. These
studies have demonstrated the ability of dogs to develop protective
immunity against the development of adult E. granulosus. Recombi-
nant proteins derived from a developmentally regulated gene family
were recently used as a vaccine to reduce numbers of the adult
cestode indogs [10]. Among antigensevaluated aspotential vaccines
in sheep, conformational epitopes of recombinant Eg95 elicited the
most protective immune response against the metacestode [19,20].
Other proteins can induce a protective effect against helmin-
thiases, including paramyosins [21–24] and tropomyosins [25,26].
Analogs of those proteins are also present in E. granulosus. EgA31, a
fibrillar protein presenting some properties of paramyosin, and
tropomyosin (EgTrp) are both expressed in the metacestode and
adult stages of E. granulosus [12,27]. EgA31 is also strongly
expressed in the immature strobilar stage of the parasite at the
level of the tegument, parenchymal cells, and immature eggs [10],
inducing an active immune response after injection, during the
infection of dogs by E.. granulosus [10,28]. Both EgA31 and EgTrp
therefore seem to be promising antigens in the development of
immunity against E. granulosus in dogs.
In the present study, these two recombinant proteins were
expressed in a mutant of S. typhimurium that had been made avirulent
in the dog, by precisely knocking out genes encoding enzymes in the
prechorismate metabolic pathway [15]. This vaccine carrier strain
has previously been used to express heterologous antigens and for
effective oral immunization of dogs [15]. In 2004, Moreno al.
demonstrated that the S. typhimurium carrier induces an immune
response in dogs [29]. Studies in calves have shown that attenuated
vaccinesbased onS.typhimuriumor S.dublincalfisolatesarecapable of
eliciting humoral and cellular immune responses, locally and at the
systemic level, to Salmonella and heterologous antigens [30–33].
Using the plasmid pTECH, which has proven high stability as part
ofa Salmonelladelivery system[13,34],we expresseda short sequence
of EgA31, including the most active epitopes [10], with the fusion
partner TetC. Such Salmonella strains can confer partial protection
against the pathogen from which the heterologous antigen was
derived. In concordance with these previous findings, the dogs in the
present studythatreceivedonlythe vectornot expressing the antigen
(group 2) showed a decrease in the number of worms compared to
control.
Few studies have been published on the immuno-phenotypical
characteristics of lymphoid cell populations in the normal canine
gut. In accordance with previous studies on the topography of T
cells [35,36], we observed a greater number of CD3+ T cells at the
top of the villi, whether the animals were infected or not. We chose
not to compare the density of CD3+ T cells obtained in the
present study with that previously reported, as these earlier studies
focused on parasite-free animals [37–39].
Our immunostaining studies indicate a decrease of more than
50% in the number of T lymphocytes in the vaccinated dogs
compared to all infected control groups, with the exception of dog
number 4, which showed a different response to the vaccine.
Only one other study has reported a l/k ratio in the dog of
around 10 in the lymph nodes [40]. In human lymphoid tissue, the
l/k ratio is around 0.5. In our dog experiments the ratio is around
5 in the intestinal mucosa, and higher in the vaccinated dogs (5.6)
compared to the infected control groups (4.9). Since the number of
k-positive cells is similar in all groups, the high l/k ratio observed
in the vaccinated group could only be due to an increase in the
number of l-positive cells.
In the present study we detected no IgG or IgE antibodies.
German et al. [35] observed a very small number (less than 15/
mm
2) of IgG-positive plasma cells in the lamina propria of the
jejunum, and identified IgE positive cells as mast cells.
.
In agreement with previous studies [35,41], we observed a
decrease in the number of plasma cells from the base to the top of
the villi and identified the main secreted immunoglobulins as IgA.
Our results indicate that the ratio of IgA to IgM is 6.9, whereas
German et al. reported it as 9.7. The vaccinated dogs in our
experiments showed a large increase in IgA-positive cells
compared with dogs receiving only Salmonella (about 40%), though
the density was similar to that in control dogs (about 5%). In light
of our results we can verify a clear imbalance in the ratio of B to T
lymphocytes in vaccinated dogs with a large decrease in the
number of T cells and a small increase in the number of B cells,
corresponding to IgA l type–secreting plasma cells.
German et al. [35] hypothesized that T lymphocytes at the top
of villi are of the Th1 lineage, whereas those at the base belong to
the Th2 lineage. The decreased number of T lymphocytes at the
top of the villi that we observed may explain the local humoral
orientation of the immune response.
In contrast to the local humoral immune response, the ELISA
results showed that the dogs developed no significant systemic
humoral immune response against the EgA31-EgTrp vaccine. The
low levels of IgG, IgA, and IgE detected in the serum showed no
difference from levels in the negative control. However, the effect
of the vaccine on the growth rate of the worms is clearly important
at the intestinal level. This contradiction between the local and
systemic immune responses after infection with E. granulosus has
been studied and described by other groups [29,42].
In conclusion, in all but one of our experimental dogs, the
Salmonella vaccine EgA31-EgTrp showed efficacy against infection
with and growth of E. granulosus. The vaccine has a local effect,
leading to a decrease in the developing adult worm burden.
Despite the fact that one dog apparently did not respond to the
vaccine, we would suggest further development and testing in field
trials. To decrease the number of worms remaining in vaccinated
dogs, it could be interesting to integrate other recombinant
proteins, such as those used by Zhang et al. [10], into our oral
vaccine. Livestock vaccination reduces the infection pressure in the
environment by decreasing the number of fertile larvae in
intermediate hosts; the addition of an oral vaccine targeted at
the adult stage of E. granulosus in dogs could help increase the
overall efficacy of control programs in endemic countries.
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